Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First gene therapy attempt for rare brain disorder begins

NCT ID NCT07173153

First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 25 times

Summary

This study tests a new gene therapy for people with SLC6A1 neurodevelopmental disorder, a rare genetic condition that affects brain function. One participant will receive a single injection of a harmless virus carrying a working copy of the SLC6A1 gene into the spinal fluid. The main goal is to check safety, and researchers will also track changes in behavior and development over three years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SLC6A1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Nationwide Children's Hospital

    Columbus, Ohio, 43205, United States

Conditions

Explore the condition pages connected to this study.